The recent emergence of effective anti-obesity medications raises the question of whether weight loss, rather than glucose control, should be considered the primary target for intervention in type 2 diabetes. Ildiko Lingvay, MD, MPH, MSCS, and Jeffrey I. Mechanick, MD, debated that question at the 82nd Scientific Sessions.
Losing weight, no matter how much or how little, has health benefits for obese people with type 2 diabetes. And the more they lose, the better the outcome, said Priya Sumithran, PhD, one of three panelists in a Scientific Session symposium that explored the use of lifestyle interventions, bariatric surgery, and pharmacotherapy to manage obesity…
In the fourth episode of the ADA Meeting News podcast series, Chair of the 82nd Scientific Sessions Meeting Planning Committee Dana Dabelea, MD, PhD, sits down with host Nick Gerik to preview Monday’s program and highlight key events taking place outside the session rooms.
Research examining central nervous system control of systemic metabolism suggests that the CNS plays an important, and perhaps a dominant role in the pathogenesis and progression of at least some forms of diabetes. Four leaders in the field, including Vincent Prevot, PhD, and Sarah Stanley, MB, BCh, PhD, will review the latest findings at the…
Cardiovascular disease is recognized as one of the most common complications of diabetes. Clinicians have long viewed coronary arterial disease and atherosclerosis as the major culprits, but heart failure has emerged as a larger problem—and one that’s more difficult to manage, according to Rong Tian, MD, PhD.
Four cardiologists, including Yi Tan, PhD (left), and Harold E. Bays, MD, will discuss the underlying mechanisms, diagnosis, and treatment of cardiomyopathy, a familiar yet underappreciated complication of diabetes. “My sense is we are on the cusp of some really interesting times in cardiomyopathy in diabetes,” Dr. Bays said.
Study investigators reported first results from the SURMOUNT-1 trial on Saturday, June 4, at the Scientific Sessions. The findings indicate that tirzepatide may be a potential therapeutic option for individuals living with obesity, said Louis J. Aronne, MD.
Otis W. Kirksey, PharmD, RPh, CDCES, BC-ADM, ADA President, Health Care & Education, discussed his dedication to the diabetes community on Saturday, June 4, saying that improving the lives of people with diabetes takes equal parts of dedication and hard work.
Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, received the ADA’s 2022 Outstanding Educator in Diabetes Award at the 82nd Scientific Sessions. Diabetes self-management education and support (DSMES) should be the standard-of-care for every person with diabetes, she said.
Davida F. Kruger, MSN, APN-BC, BC-ADM, told women at the Saturday afternoon symposium that if they’re not invited to the table, show up anyway—with a chair. And keep moving that chair closer and closer to the table.